Biofield diagnostic system

Biofield diagnostic system

A diagnostic system that uses sensors (similar to EKG) that fire electropotential signals through tissue to distinguish between benign and malignant lesions.

The system is not FDA approved for commercial marketing or use.
References in periodicals archive ?
It offers Biofield Diagnostic System, a breast cancer diagnostic device, which employs single-use sensors to measure and analyze changes in cellular electrical charge distributions associated with the development of epithelial cancers, such as breast, ovaries, skin, prostate, and colon cancers.
the developer of an investigational breast bioelectric potential measurement method known as the Biofield Diagnostic System (BDS).
The Biofield Diagnostic System was evaluated in a study of 661 women at eight leading European medical centres who had undergone a biopsy for suspicious breast lesions.
OTCBB:BZEC), today announced that it has shipped the initial order of its proprietary Biofield Diagnostic System for the early detection of breast cancer units (the "BDS"), to an exclusive distributor representing the Mexican, Central and Latin American markets.
FDA approval to distribute the Company's proprietary Biofield Diagnostic System for the early detection of breast cancer (the "BDS") in the U.
is a developmental stage medical technology company that has developed the Biofield Diagnostic System (BDS), a device for detecting breast cancer in a non-invasive procedure.
Biofield Corporation (OTC Bulletin Board: BZET), developer of the Biofield Diagnostic System (BDS), a non-invasive, radiation-free diagnostic testing system used for early detection of breast cancer, announced today that it has signed a three-year exclusive distribution agreement for Malaysia with Biofield Diagnostic Systems Sdn Bhd.
The Company's breast cancer diagnostic device, the Biofield Diagnostic System (BDS), employs single-use sensors designed by Biofield and a measurement device to detect and analyze changes associated with the development of epithelial cancers, such as breast cancer.
The agreement grants Trilogy Critical Care the exclusive right to market and sell the Biofield Diagnostic System (BDS) in South Africa and certain other southern African countries during the three-year period commencing December 1, 2001, conditioned on achieving annual minimum sales.
The new China HQ will oversee and manage the Carelife JVs, which will distribute, test, further develop, and gather critical medical data from the Biofield Diagnostic System (BDS) and other medical technology in conjunction with leading Chinese governmental healthcare organizations, hospitals, testing centers, doctors, medical organizations, insurance companies, and banks.
is a medical technology company that has developed, patented, and completed clinical testing of the Biofield Diagnostic System for use in diagnosing breast cancer.
is a development-stage medical technology company that has developed a device to assist in detecting breast cancer in a non-invasive procedure, the Biofield Diagnostic System (BDS).